1100 13th Street, NW, Suite 750Washington, DC 20005202.887.6400Toll-free: 800.544.0155
All Contents © 2018The Kiplinger Washington Editors
Follow columnist Kathy Kristof as she shares lessons from her real-life investment portfolio.
FREE - Get the best of kiplinger.com (including Practical Investing) by E-mail
The market ran so fast that the relatively conservative portfolio of Kiplinger's Practical Investor simply couldn't keep up.
See More On: Stocks & Bonds | Index Funds
Tesla gets all the attention, but with actual profits, GM can afford to finance innovation.
See More On: Stocks & Bonds
When you've got a novel to write, but still have bills to pay, well-timed stock sales can help keep the balance.
See More On: Stocks & Bonds | Saving for Retirement
Though Apple is already largest holding in my portfolio, I'm sorely tempted to buy more.
See More On: Tech Stocks | Stocks & Bonds
It may seem like you’re facing the storm of the century every time you turn on the news, but the markets have survived far worse.
See More On: Stocks & Bonds | Economic Forecasts
One pick, Lazard, is a global investment banking firm. Its reasonable share price provides a margin of safety.
Intel’s purchase of
Mobileye is its
in the past two
years, but Intel
doesn’t have a
stellar history when
it comes to big
See More On: Stocks & Bonds | Tech Stocks
I've been sorely tempted to sell my Gilead shares. But now that they're cheaper, maybe I should buy more.
Gilead Sciences' robust product pipeline should turn things around.
A well-considered spin-off can increase the value of both parent and child by allowing each to focus on a narrower set of goals.
A portfolio without FANGs was doomed to have trouble last year.
Selling quality stocks was just one of the mistakes.
See More On: Investor Psychology
For the three-month period during which I essentially ignored my investments, the Practical Investing portfolio rose 10%.
See More On: Stocks & Bonds | Investor Psychology
This small homebuilder's first-quarter results were impressive, with big gains in number of dwellings sold and other key measures.
Gilead Sciences stock was selling for a mere 7 times estimated 2016 earnings when I snapped up 150 shares.
Constantly checking market results practically begs you to do something, even if doing nothing is the best course.
Because I'm a diehard bargain hunter, I find Apple's stock too cheap to pass up.